MRE-269

MRE-269 is an active metabolite of selexipag, and acts as a selective IP receptor agonist.

Product Specifications

CAS Number

[475085-57-5]

Product Name Alternative

ACT-333679

UNSPSC

12352005

Hazard Statement

H302, H312, H332

Target

Prostaglandin Receptor

Type

Natural Products

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease; Endocrinology

Assay Protocol

https://www.medchemexpress.com/MRE-269.html

Purity

99.14

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

OC(COCCCCN(C(C)C)C1=NC(C2=CC=CC=C2)=C(C3=CC=CC=C3)N=C1)=O

Molecular Formula

C25H29N3O3

Molecular Weight

419.52

Precautions

H302, H312, H332

References & Citations

[1]Fuchikami C, et al. A comparison of vasodilation mode among selexipag (NS-304; [2-{4-[ (5,6-diphenylpyrazin-2-yl) (isopropyl) amino]butoxy}-N- (methylsulfonyl) acetamide]), its active metabolite MRE-269 and various prostacyclin receptor agonists in rat, porcin|[2]Orie NN, et al. Differential actions of the prostacyclin analogues treprostinil and iloprost and the selexipag metabolite, MRE-269 (ACT-333679) in rat small pulmonary arteries and veins. Prostaglandins Other Lipid Mediat. 2013 Oct;106:1-7|[3]Kuwano K, et al. A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[ (5,6-diphenylpyrazin-2-yl) (isopropyl) amino]butoxy}-N- (methylsulfonyl) acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses